drugset / Trial / NCT06724289
Psilocybin for Prolonged Grief Disorder
Phase 0
Recruiting
12 enrolled
University of Virginia
Texas Tech University · collabTiny Blue Dot Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
Timeline
- Start
- 2026-03-24
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | — |
Indications
No indication recorded.